Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 366

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 8
Chunk 366
---
12,167,679

    $
    12,168

    $
    86,887,170

    $
    (88,474,997
    )
     
    $
    (1,558,746
    )

      The accompanying notes to the consolidated financial statements are an integral part of this statement.
      F-7

TUHURA BIOSCIENCES, INC AND SUBSIDIARIESConsolidated statements of stockholders’ equity (deficit) continuedFor the years ended December 31, 2024, and 2023  

    Total

    Additional

    Accumulated

    Stockholders'

    Preferred Stock

    Common Stock

    Paid in

    Equity

    Equity

    Shares

    Dollars

    Shares

    Dollars

    Capital

    (Deficit)

    (Deficit)

    Balances at January 1, 2024
     
    16,912,843

    $
    16,913

    12,167,679

    $
    12,168

    $
    86,887,170

    $
    (88,474,997
    )
     
    $
    (1,558,746
    )

    Conversion of preferred stock to common stock
     
    (16,912,843
    )

    (16,913
    )

    16,912,843

    16,913

    -

    -

    -

    Issuance of common stock upon settlement of   convertible notes
     
    -

    -

    9,866,756

    9,867

    24,879,782

    -

    24,889,649

    Reclassification of the derivative liability associated   with the convertible notes make-whole premium
     
    -

    -

    -

    -

    2,853,000

    -

    2,853,000

    Common stock and preferred stock (assumed from   merger) to Kintara shareholders in reverse   recapitalization
     
    278,530

    278,530

    1,842,920

    1,843

    (1,627,285
    )

    -

    (1,346,912
    )

    Transaction costs in connection with the reverse   recapitalization
     
    -

    -

    -

    -